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Background: Atrial fibrillation (AF) prevalence increases significantly with age. Little is known about
the effect of AF ablation on quality of life and healthcare utilization in the elderly. The objective of this
study was to quantify the healthcare utilization and quality of life benefits of catheter ablation for AF, for
patients 65 years compared to patients <65 years.
Methods: Two multicenter U.S. registry studies enrolled patients with paroxysmal AF. Baseline
characteristics and acute outcomes were collected for 736 patients receiving catheter ablation with
the NAVISTAR R© THERMOCOOL R© SF Catheter (Biosense Webster, Inc., Diamond Bar, CA, USA). Healthcare
utilization and quality of life outcomes were collected through 1 year postablation for 508 patients.
Results: The rates of acute pulmonary vein isolation were high and similar between patients
65 years and <65 years (97.5% vs 95.8%, P = 0.2130). Length of stay for the index procedure was
similar between age groups with 82.2% of the older group and 83.2% of the younger group having one-
day hospitalization. Disease-specific quality of life instrument scores improved significantly and similarly
for older and younger patients at 1 year postablation, compared to baseline. AF-related hospitalizations
and emergency department visits were similar or lower in older patients compared to younger patients,
as reported at 1 year postablation.
Conclusion: For older patients undergoing catheter ablation for paroxysmal AF, healthcare utilization
parameters were lower or not significantly different than for younger patients, and quality of life outcomes
were similarly improved. These findings support the use of catheter ablation as a treatment option in older
patients with paroxysmal AF. (PACE 2017; 40:391–400)
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Introduction
Atrial fibrillation (AF) is the most common
sustained arrhythmia, and studies show that its
prevalence and incidence continue to rise.1 The
risk of developing AF increases significantly with
age and accelerates in patients over 65 years
of age.1,2 Radiofrequency ablation is currently
recommended as a second-line therapy in patients
with symptomatic paroxysmal and persistent AF
after at least one antiarrhythmic drug (AAD) has
failed.3 Even though the average age of patients
undergoing AF ablation procedures has been
increasing in recent years, there is a paucity of
information regarding AF ablation outcomes in
the elderly.3,4 The few studies that do report on
AF ablation in elderly populations have focused
primarily on safety and AF recurrence.5–8
Patients suffering from AF commonly de-
scribe considerable impairment in quality of
life (QoL).9,10 Improvement in QoL following
treatment of AF has been shown to be directly
correlated with the restoration and maintenance
of a normal sinus rhythm (NSR).9–12 However, it
is unclear whether older patients experience an
improved QoL after catheter ablation. Therefore,
there is a need to better understand the com-
prehensive effects of catheter ablation in older
populations.
This analysis summarizes patient outcomes
utilizing data collected in two prospective
multicenter observational registry studies (SFAF
and IUAF) in the United States. Both studies
were designed to measure “real-world” acute
procedural outcomes associated with the use of the
NAVISTAR R© THERMOCOOL R© SF Ablation Catheter
(Biosense Webster, Inc., Diamond Bar, CA, USA)
in a clinical setting in patients with symptomatic
paroxysmal AF refractory to at least one
antiarrhythmic agent. In addition, the SFAF study
evaluated the effect of the ablation procedure
on healthcare utilization, QoL, and employment
status through 1 year postprocedure. The primary
objective of this paper is to report on the clinical
effectiveness and healthcare utilization outcomes
of the SFAF and IUAF studies and the impact of
catheter ablation on health-related QoL measures.
Methods
Study Design
The NAVISTAR R© THERMOCOOL R© SF Catheter:
Observational Study (SFAF) and CARTO R©3 System
and Real Time Intracardiac Ultrasound (IUAF)
registry studies included patients who were
18 years or older with drug-refractory, recurrent,
symptomatic, paroxysmal AF and no prior ab-
lation for their AF. The SFAF study included
45 U.S. clinical centers, with outcomes evaluated
during RFA, immediately post-RFA, at discharge,
at day 7, and at 6 and 12 months. The IUAF
study included 26 U.S. sites, with outcomes
evaluated during RFA, immediately post-RFA, at
discharge, and at day 7. This analysis combines
acute endpoints from the SFAF and IUAF studies
and includes available information for clinical
effectiveness and utilization outcomes at the time
that the databases were locked.
Study Population
A total of 736 patients were enrolled in the
two studies and had ablations performed with
the study catheter: 508 from the SFAF study
and 228 from the IUAF study (Table I). Of the
total, 381 were <65 years of age (264 SFAF,
117 IUAF) and 355 were 65 years of age or older
(244 SFAF, 111 IUAF). The mean age of the older
group was 71.1 with standard deviation (SD) of
4.9 years (range 65–85). The mean age of the
younger group was 53.6 years with SD of 9.1
(range 23–64). Significant differences in baseline
characteristics in the older versus younger patients
included the following: fewer males; higher rates
of anticoagulation usage, hypertension, transient
ischemic attack, and coronary artery disease; and
higher CHADS2 risk scores (Table I).
AF Ablation Procedure
The AF ablation procedures included pul-
monary vein isolation performed with a 56-
hole porous-tip ablation catheter (NAVISTAR R©
THERMOCOOL R© SF Catheter) and three-dimensional
(3D) electroanatomical mapping (CARTO R© 3
System, Biosense Webster, Inc.). All of the IUAF
procedures and some of the SFAF procedures
also included use of the SOUNDSTAR R© Catheter
for 3D intracardiac echocardiography. Ablation
methodology was at the discretion of the operators
with minimal recommendations, as reported
previously for these trials.6
Statistical Analysis
Descriptive statistics were used to summarize
pooled procedural data from both studies and
1-year endpoints from the SFAF study. Contin-
uous data were expressed as means and SDs.
Categorical outcomes were presented as the
number and percentages of events.
Study Endpoints and Definitions
The IUAF study followed patients for only
7 days postablation, collecting data on acute
procedural success, procedural efficiency, and
adverse events. The SFAF study followed patients
through 12 months postablation, collecting the
same acute endpoints, as well as information
on healthcare utilization measures including
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Table I.
Baseline Patient Characteristics
Overall Patients <65 Years Patients 65+ Years
Category n Percent n Percent n Percent
Total N 736 100% 381 100.0% 355 100%
Study
IUAF 228 31.0% 117 30.7% 111 31.3%
SFAF 508 69.0% 264 69.3% 244 68.7%
Sex‡
Female 284 38.6% 126 33.1% 158 44.5%
Male 452 61.4% 255 66.9% 197 55.5%
Anticoagulant usage* 615 83.6% 306 80.3% 309 87.0%
Baseline comorbidities
Hypertension§ 503 68.3% 224 58.8% 279 78.6%
Diabetes 131 17.8% 64 16.8% 67 18.9%
Pulmonary disease 42 5.7% 20 5.2% 22 6.2%
Congestive heart failure 62 8.4% 30 7.9% 32 9.0%
NYHA I 18 2.4% 8 2.1% 10 2.8%
NYHA II 42 5.7% 20 5.2% 22 6.2%
NYHA unknown 2 0.3% 2 0.5% 0 0.0%
Stroke - Thromboembolic 13 1.8% 5 1.3% 8 2.3%
Stroke - Not Thromboembolic 9 1.2% 5 1.3% 4 1.1%
Transient ischemic attack* 30 4.1% 9 2.4% 21 5.9%
Coronary artery disease§ 159 21.6% 53 13.9% 106 29.9%
Obesity 172 23.4% 101 26.5% 71 20.0%
CHADS2 Risk Score§
0 205 27.9% 144 37.8% 61 17.2%
1 308 41.8% 158 41.5% 150 42.3%
2 157 21.3% 56 14.7% 101 28.5%
3 51 6.9% 20 5.2% 31 8.7%
4 13 1.8% 3 0.8% 10 2.8%
5 2 0.3% 0 0.0% 2 0.6%
6 0 0.0% 0 0.0% 0 0.0%
Cardiac Measures Mean SD Mean SD Mean SD
Left atrial size (mm) 42.4 25.8 43.5 33.7 41.1 11.3
Ejection fraction 57.8% 8.6% 57.5% 8.4% 58.1% 8.8%
IUAF = Registry Identifier; NYHA = New York Heart Association; SFAF = Registry Identifier.
*P-value for difference between younger and older patients is 0.05.
†P-value for difference between younger and older patients is 0.01.
‡P-value for difference between younger and older patients is 0.001.
§P-value for difference between younger and older patients is 0.0001.
inpatient length of stay (LOS), repeat ablations
procedures, repeat hospitalizations, emergency
department visits, and outpatient office visits; and
QoL measures including Atrial Fibrillation Effect
on Quality of Life (AFEQT) score and lost work
days. Acute procedural success was defined as
isolation of all targeted pulmonary veins. LOS was
calculated as the total length of the index ablation
visit, and also as the subset of days from the
ablation procedure to hospital discharge. Patients
with total LOS > 1 week were investigated to
determine whether the increased LOS was due
to an extended preablation visit, exacerbation of
a comorbid event, or a procedure-related adverse
event. Outcomes of interest were also summarized
by age cohort to compare younger patients
(<65 years of age) versus older patients (age
65 years and over).
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All outcomes were summarized for the total
population of enrolled patients who underwent
catheter ablation with the study catheter and
who had complete data. QoL was measured
with a disease-specific instrument, the AFEQT
Questionnaire.13 This instrument produces an
overall QoL score, along with three scores for
subscales relating to symptoms, daily activities,
and treatment concern. In addition, it includes
two questions related to patient satisfaction
that are scored independently and not included
in the overall score. In brief, higher AFEQT
scores correlate with self-reported improvement in
symptoms. Employment status at baseline, along
with any changes in status, was reported at 6
and 12 months postablation. Lost work days due
to any cause and specifically due to AF were
also recorded at the 6- and 12-month postablation
visits.
All statistical comparisons of continuous data
utilized t-tests and all statistical comparisons of
count data utilized Pearson’s χ2 tests. All analyses
were performed using SAS version 9.2 (SAS
Institute Inc., Cary, NC, USA).
Results
Procedural Success
Acute procedural success (i.e., pulmonary
vein isolation in all targeted veins) was achieved
in 711 of 736 patients (96.6%). The acute success
rate was not significantly different in older versus
younger cohorts (97.5% vs 95.8%, P = 0.2130)
or in females versus males (97.9% vs 95.8%,
P = 0.1274) (Table II).
Patient Follow-Up
All 736 patients who had ablations performed
with the study catheter also had procedural detail
and acute safety information available. Of the
508 patients in the longer SFAF study, six died
during the follow-up period and 23 were lost to
follow-up, leaving 479 patients with 12-month
visits.
LOS
The majority of patients had a total LOS
of 1 day, with no significant difference between
younger versus older cohorts (78% overall, 79%
of patients <65, 77% of patients 65+). The overall
distribution of total LOS was not different between
age cohorts (P = 0.3327), nor was the distribution
of days from procedure to discharge (P = 0.7503).
A total of 11 patients had postablation LOS of >5
days, of whom three were <65 years, six were 65–
74 years, and two were 75+ years. Of these patients
with extended hospital stays, four had serious
adverse events (SAEs) that were adjudicated to be
related to the procedure or the device, including
two cardiac tamponades in patients <65 years
and two vascular access complications in patients
65+ years. An additional six of the patients with
extended LOS, all of whom were 65+ years, had
Table II.
Ablation Outcomes
Total Population Patients <65 Years Patients 65+ Years
N Count Percent N Count Percent N Count Percent
Length of Stay after Ablation
0 days 735 17 2.3% 381 9 2.4% 354 8 2.3%
1 day 735 608 82.7% 381 317 83.2% 354 291 82.2%
2 days 735 58 7.9% 381 31 8.1% 354 27 7.6%
3 days 735 22 3.0% 381 12 3.1% 354 10 2.8%
4 days 735 9 1.2% 381 5 1.3% 354 4 1.1%
5 days 735 10 1.4% 381 4 1.0% 354 6 1.7%
>5 days 735 11 1.5% 381 3 0.8% 354 8 2.3%
Acute success (isolation of
PVs)
736 711 96.6% 381 365 95.8% 355 346 97.5%
Repeat ablations 508 74 14.6% 264 39 14.8% 244 35 14.3%
N Mean (SD) Range N Mean (SD) Range N Mean (SD) Range
Days to 1st Repeat Ablation 74 172 (91) (16, 429) 39 175 (85) (16, 349) 35 168 (99) (20, 429)
PV = pulmonary vein; SD = standard deviation.
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Table III.
Healthcare Utilization Reported at 12 Months Postablation
































139 28.4 1 80 34.0 1 59 23.2 1
Outpatient
emergency visit
120 24.5 1 64 27.2 1 56 22.0 1
Outpatient office
visit§




73 14.9 1 40 17.0 2 33 13.0 1
Outpatient
emergency visit
56 11.5 1 23 9.8 1 33 13.0 1
Outpatient office
visit*
323 66.1 10 167 71.1 10 156 61.4 8
*P-value for difference between younger and older patients is 0.05.
†P-value for difference between younger and older patients is 0.01.
‡P-value for difference between younger and older patients is 0.001.
§P-value for difference between younger and older patients is 0.0001.
unrelated SAEs. One patient<65 years had a 9-day
LOS with no reported adverse events. In addition,
three patients with only 2–3 days from procedure
to discharge were admitted 8–13 days prior to
the procedure, resulting in extended total stays
(Table II).
Repeat Ablations
A total of 74 patients (14.6%) of 508 in the
SFAF study had repeat ablations occurring prior to
their 12-month follow-up visit. The repeat ablation
rate was similar in the younger and older cohorts
(14.8% vs 14.3%). For those patients with repeat
ablations prior to their 12-month visit, the mean
time to reablation was 172 days (SD 91 days), and
the difference in distribution of times between the
older and younger cohorts was not statistically
significant (age <65: mean 175 days, SD 85 days;
age 65+: mean 168 days, SD 99 days) (Table II).
Repeat Hospitalizations, ED Visits, and
Outpatient Visits
All-cause hospitalization rates were signif-
icantly lower in the older cohort than in the
younger cohort (34.0% vs 23.2%, P = 0.0081).
AF-related hospitalization rates were lower in
the older cohort than in the younger group but
the difference was not statistically significant
(13.0% vs 17.0%, P = 0.2620). The percentage
of patients with all-cause outpatient emergency
visits was higher in the younger cohort, whereas
the percentage with AF-related visits was higher
in the older cohort, but neither difference was
statistically significant (P = 0.1830 and P =
0.2080). Significantly more younger patients than
older patients reported outpatient office visits,
both for all-cause and specifically for AF (P <
0.0001 and P = 0.0182) (Table III).
QoL
Of the 508 patients in the SFAF study, 506 had
completed AFEQT surveys at screening and 464
had completed surveys at their 1-year follow-up
visit, resulting in 462 patients for whom a change
in the scale score could be calculated. These
patients showed substantial improvement in QoL
at 1 year after ablation in all subscale categories
(Fig. 1A). On scales ranging from 0 (lowest QoL
score on every question) to 100 (highest QoL score
on every question), patients scored an average
of 33 points higher at 1 year postablation than
they did preablation. Gains of 35–38 points,
on average, were realized in each subscore for
categories related to symptoms, daily activities,
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Figure 1. (A) Mean AFEQT scores at baseline versus 12-month visit by age group. (B) Mean AFEQT scores at baseline
versus 12-month visit by sex. AFEQT = atrial fibrillation effect on quality of life.
and treatment concerns. In addition, summary
questions regarding patient satisfaction with both
AF control and symptoms doubled from baseline
levels.
AFEQT score increases were similar in older
and younger patients, with increases in the
younger patients of just a few points more than
in older patients across all subscores and patient
satisfaction questions (P-values for age cohort
ranging from 0.3016 for the overall score to 0.4948
for patient satisfaction with symptoms) (Fig. 1A).
All AFEQT scores increased significantly from
396 April 2017 PACE, Vol. 40
UTILIZATION/QOL AFTER AF ABLATION
baseline to the 12-month follow-up visit and were
greater for females than for males as a result of
female patients having lower baseline scores, but
similar 12-month scores (P-values for sex ranging
from <0.0001 for the overall score to 0.0501 for
patient satisfaction with symptoms) (Fig. 1B).
Though this study was designed to compare
patients age 65 and over versus patients<65 years,
gains in overall QoL scores from the AFEQT were
similar even in the more senior patients within
the older cohort, though sample sizes dropped
off substantially with advancing age. Mean gains
in the overall AFEQT scale from baseline to
12 months were 37.1 for age < 65 years (N = 236)
and 34.8 for patients age 65+ years (N= 226), with
a gain of 30.1 in the subset of age 75+ years (N =
53) and a gain of 34.2 in the subset of age 80+ years
(N = 14).
In order to further understand how the
observed increases in QoL scores could potentially
be impacted by patient characteristics that differ
with age, we ran a regression model to adjust
for the differences seen between the older and
younger patients at baseline. The change in total
AFEQT score from baseline was significantly
impacted only by a patient’s baseline AFEQT
score (P < 0.0001). Sex, age group, CHADS2 score,
anticoagulation usage, hypertension, transient
ischemic attack, and coronary artery disease did
not affect the patient’s improvement in QoL
(P-value range: 0.2535–0.9483).
Discussion
The prevalence of AF in the United States is
estimated at 3 million, affecting one in 25 adults
60 years of age and almost one in 10 80 years
of age.14,15 These rates are expected to increase
2.5-fold in the next 50 years, with a disproportion-
ate increase in older adults.14 In addition, given
the older age of the patients, patients with AF
have a high burden of comorbidities, with many of
these being risk factors for stroke in AF, including
hypertension, diabetes, and heart failure.16 AF, as
well as these comorbidities, have been shown to
directly impact health-related QoL.16,17 Therefore,
research investigating the utilization and benefit
of AF ablation in elderly patients is critical.
Healthcare Utilization
The benefits of catheter ablation in the elderly
population are increasingly being reported.4–8,14,16
In a study of patients undergoing ablation at
Johns Hopkins Hospital, Hoyt et al. reported some
important trends: a steady increase in the number
of ablation procedures (25 in 2001 vs 142 in 2005)
and repeat procedures (four in 2001 vs. 56 in
2009), an increase in the mean age of patients
undergoing ablation (52 years in 2001 vs 60 years
in 2009), a shorter duration of AF prior to referral
for ablation (7.8 years in 2001 vs 4.2 years in
2009), and a decrease in the number of AADs used
prior to first ablation (2.3 vs 1.2).4 In a population
of 261 AF patients 75 years old undergoing
catheter ablation, 83% remained in NSR with
lower mortality and stroke risks at mean follow-up
time of 3 ± 2.5 years.8 In a study by Corrado et al.,
73% of septuagenarians maintained sinus rhythm
with a single ablation procedure over a mean
follow-up period of 20 ± 14 months.5 Wokhlu
et al. reported freedom from recurrence in 69%
of patients at 2 years follow-up.18
In this study, all of the longer-term healthcare
utilization and QoL endpoints showed similar
results for younger and older patients. These
findings enhance previous studies that reported
healthcare utilization in AF ablation patients.
Bulkova et al. reported a decrease in the hospital
admission rate from 48% before index ablation to
25%, 17%, and 8% in the subsequent 3 years in
patients with paroxysmal AF.19 Both all-cause and
AF-related readmission rates were lower in the
SFAF study than in a published study reporting on
utilization after ablations that occurred between
2005 and 2008 using the California State Inpatient
Database.20
QoL
An important goal of AF catheter ablation
procedures is to improve patients’ QoL. In the
AF population, QoL improves with treatment and
improvement is associated with maintenance of
NSR.5,8,12,21 For older patients, QoL has been
shown to significantly decrease with increasing
age22 and AF ablation has been shown to signif-
icantly improve the QoL in AF patients.12,22–27
Quantification of symptom improvement through
assessment of health-related QoL is a critical
component in evaluating patient outcomes and
clinical effectiveness of AF ablation.26,28 The
AFEQT is a disease-specific questionnaire that has
been shown to be valid, reliable, and sensitive to
clinical change in patients with AF.29
In this study, the AFEQT showed substantial
improvement in QoL at 1 year after ablation
compared to baseline in all subscale categories.
QoL was improved significantly in the older
cohort of patients 65 years and this improvement
appeared to remain stable for subsets of patients
age 75+ and 80+ years. These findings enhance
the findings previously reported in several studies,
which largely reported QoL improvements undif-
ferentiated by age.18,23–25,27
Study Limitations
The primary limitation of this study is that
the data are derived from single-arm prospective
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observational cohorts rather than from random-
ized controlled trials. For this reason, the studies
may represent a group of patients undergoing
ablation procedure that have a more favorable
risk profile than the overall AF population. In
particular, the elderly patients may be healthier
than average AF patients their age, potentially
representing the most robust of this elderly
population. Nevertheless, several studies have
shown that of the elderly who do present for
ablation, outcomes are favorable when compared
with the younger population.5,6,8 In addition,
“real-world” studies such as this provide valu-
able complementary information and insights to
data derived from randomized controlled trials
due to fewer inclusion and exclusion criteria
and a broader range of participating clinical
sites.
Another limitation of the SFAF study is the
potential for bias in the 1-year endpoints due to
an outcome differential between patients who
were lost to follow-up or had missing endpoints
and those who had nonmissing endpoints. This is
related to the limitation discussed above in that
a single-arm observational study does not allow
for a comparison of the rates of missing values
between cohorts. It is important to note that the
findings of this study apply only to patients with
paroxysmal AF, and should not be extrapolated to
patients with persistent/chronic AF. In addition,
the collection of postablation rhythm status and
AAD therapy were beyond the scope of the data
collection for these clinical trials, thus precluding
analysis of AF recurrence.
Conclusions
Catheter ablation with the NAVISTAR R©
THERMOCOOL R© SF Ablation Catheter is associated
with improved outcomes for both younger and
older patients with nonvalvular paroxysmal AF.
AF ablation in older patients was not associated
with increased LOS, repeat ablations, AF-related
repeat hospitalizations, or emergency department
visits during the 12 months postablation when
compared to a younger group. QoL endpoints were
also similar for older versus younger patients,
including AFEQT score improvement and number
of lost work days. AF ablation in patients 65
years is an effective strategy for longer-term
improvement of both healthcare utilization and
QoL.
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Appendix
SFAF Study (45 U.S. centers)
1. Central Baptist Hospital (Lexington, KY) –
Dr. Gery Tomassoni
2. Florida Hospital (Orlando, FL) – Dr. Scott
Pollak
3. Scottsdale Healthcare Research Insti-
tute, Scottsdale Healthcare/Shea Medical Center
(Scottsdale, AZ) – Dr. Andy Tran
4. St. Vincent’s Ambulatory Care, Inc. (Jack-
sonville, FL) – Dr. Saumil Oza
5. Alaska Heart Institute, LLC. (Anchorage,
AK) – Dr. Steven Compton
6. St. Joseph’s Hospital of Atlanta/Emory
University (Atlanta, GA) – Dr. Anshul Patel
7. JFK Medical Center (Atlantis, FL) – Dr.
Robert Fishel
8. Cardiovascular Research Foundation of
Louisiana (Baton Rouge, LA) – Dr. Kenneth Civello
9. Bethesda North Hospital (Cincinnati, OH)–
Dr. Gaurang Gandhi
10. University of Cincinnati (Cincinnati,
OH)– Dr. Alexandru Costea
11. Riverside Methodist Hospital (Columbus,
OH) – Dr. Sreedhar Billakanty
12. Florida Hospital Memorial Medical Cen-
ter (Daytona Beach, FL) – Dr. James Wang
13. Central Bucks Specialists, LTD.
(Doylestown, PA) – Dr. John Harding
14. Alexian Brothers Medical Center (Elk
Grove Village, IL) – Dr. Mohammad Khan
15. Baylor All Saints Medical Center (Fort
Worth, TX) – Dr. Vijay Jayachandran
16. Lutheran Medical Group, LLC., Northern
Indiana Research Alliance (Fort Wayne, IN) – Dr.
Sree Karanam
17. Plaza Medical Center (Grapevine, TX) –
Dr. Craig Delaughter
18. Bellin Memorial Hospital, Inc. (Green
Bay, WI) – Dr. Mohammad Jazayeri
19. Texas Heart Institute at St. Luke’s Episco-
pal Hospital (Houston, TX) – Dr. Abdi Rasekh
20. Heart Center Research, LLC., Huntsville
Hospital (Huntsville, AL) – Dr. Scott Allison
21. University of Iowa Hospital and Clinics
(Iowa City, IA) – Dr. Alexander Mazur
22. University of Kansas Hospitals (Kansas
City, KS) – Dr. Dhanunjaya Lakkireddy
23. St. Luke’s Mid America Heart Institute
(Kansas City, MO) – Dr. Alan Wimmer
24. Scripps Clinical Research, Scripps
Memorial Hospital (La Jolla, CA) – Dr. Ali Hamzei
25. Largo Medical Center (Largo, FL) – Dr.
Shalin Shah
26. Brian LGH Heart Institute (Lincoln, NE) –
Dr. Michael Kutayli
27. Baptist Hospital East (Louisville, KY) –
Dr. John Mandrola
28. North Shore University Hospital (Mah-
nasset, NY) – Dr. Stuart Beldner
29. University of Chicago Medical Center
(Chicago, IL) – Dr. Joshua Moss
30. Centennial Medical Center (Nashville,
TN) – Dr. Greg Bashian
31. Vanderbilt Heart and Vascular Institute
(Nashville, TN) – Dr. Patrick Whalen
32. New York Presbyterian Hospital,
Columbia University Medical Center (New
York, NY) – Dr. Angelo Biviano
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33. Creighton University Medical Center
(Omaha, NE) – Dr. Hussam Abuissa
34. Albert Einstein Medical Center (Philadel-
phia, PA) – Dr. Sumeet Mainigi
35. San Diego Cardiac Center, Sharp Memo-
rial Hospital (San Diego, CA) – Dr. Charles Athill
36. UCSF Medical Center (San Francisco,
CA) Dr. Edward Gerstenfeld
37. St. Joseph’s Hospital, Savannah (Savan-
nah, GA) – Dr. Michael Chisner
38. Arizona Heart Hospital (Phoenix, AZ) –
Dr. Vijendra Swarup
39. St. John’s Hospital (Springfield, IL) – Dr.
Ziad Issa
40. Cardiac Study Center Inc., P.S. (Tacoma,
WA) – Dr. Tariq Salam
41. Washington Adventist Hospital (Takoma
Park, MD) – Dr. Sung Lee
42. Gensesis Healthcare Systems (Zanesville,
OH) – Dr. Magdy Migeed
43. Morristown Medical Center (Morristown,
NJ) – Dr. Jonathan Sussman
44. Tampa General Hospital (Tampa, FL) –
Dr. Bengt Herweg
45. United Heart & Vascular Clinic, United
Hospital (St. Paul, MN) – Dr. Pierce Vatterott
IUAF Study (26 U.S. centers)
1. Osceola Regional Medical Center (Kissim-
mee, FL) – Dr. Usman Siddiqui
2. Hospital of the University of Pennsylvania
(Philadelphia, PA) – Dr. Mathew Hutchinson
3. Scottsdale Healthcare Research Institute
(Scottsdale, AZ) – Dr. Andy Tran
4. St. Vincent’s Ambulatory Care, Inc. (Jack-
sonville, FL) – Dr. Saumil Oza
5. JFK Medical Center (Atlantis, FL) – Dr.
Robert Fishel
6. Arizona Heart Hospital (Phoenix, AZ) – Dr.
Vijendra Swarup
7. Washington Adventist Hospital (Takoma
Park, MD) – Dr. Mohit Rastogi
8. Santa Barbara Cottage Hospital (Santa
Barbara, CA) – Dr. Brett Gidney
9. University of Nebraska Medical Center
(Omaha, NE) – Dr. John Scherschel
10. Pepin Heart Hospital (Tampa, FL) – Dr.
Dilip Mathew
11. University of Colorado, Denver (Aurora,
CO) – Dr. William Sauer
12. Medical College of Wisconsin (Milwau-
kee, WI) – Dr. Marcie Berger
13. Kettering Medical Center (Kettering,
OH) – Dr. Shahid Baig
14. Tallahassee Research Institute, Inc. (Tal-
lahassee, FL) – Dr. Farhat Khairallah
15. Scott & White Memorial Hospital (Tem-
ple, TX) – Dr. Taresh Taneja
16. Geisinger Wyoming Valley Medical Cen-
ter (Wilkes-Barre, PA) – Dr. Gopi Dandamudi
17. Provena St. Joseph Medical Center (Joliet,
IL) – Dr. Ahmad Karim
18. Lankenau Institute for Medical Research
(Wynnewood, PA) – Dr. Douglas Esberg
19. St. Mary Medical Center (Newtown,
PA) – Dr. Scott Burke
20. Wellmont Holston Valley Medical Center
(Kingsport, TN) – Dr. Gregory Jones
21. The Methodist Hospital Research Institu-
tion (Houston, TX) – Dr. Tapan Rami
22. Northeast Georgia Heart Center, PC
(Gainesville, GA) – Dr. Salem Sayar
23. Hackensack University Medical Center
(Hackensack, NJ) – Dr. Gunjan Shukla
24. Sentara Norflok General Hospital (Nor-
folk, VA) – Dr. Philip Gentlesk
25. Covenant Medical Center (Saginaw, MI) –
Dr. Asim Yunus
26. Northeast Baptist Hospital (San Antonio,
TX) – Dr. Stephen Reich
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